60 Degrees Pharmaceuticals
SXTP on Nasdaq. Market value $2m.
Should I look at this?
Look carefully before going further
Why it could be worth it
Nothing stands out yet.
What to watch out for
Read the warning sign in its own filings
This is not advice.
Who owns it
None of the long-term investors we follow own it. 8 funds in all.
Largest holders overall
- Kathmere Capital Management$466,576Added
- Citadel Advisors$39,357New
- XTX Topco$31,045New
- Kovack Advisors$26,400New
- Geode Capital Management$25,608Cut
- UBS Group AG$23,922Cut
- Barclays$1,851Cut
- Osaic Holdings$44
From 13F filings for the quarter ended 30 June 2026.
Big holders and activists
7 investors own more than 5%.
- Knight Therapeutics Inc.Passive investor19.9%+19.9 ptsSince 22 July 2026
- Mitchell P. KopinPassive investorat least 10.0%+0.9 pts(filed with 2 related holders)Since 30 September 2026
- Orca Capital AGPassive investor5.6%+0.7 ptsSince 5 November 2026
- Lind Global Fund III LPPassive investorat least 5.5%(filed with 2 related holders)Since 31 July 2026
- CVI Investments, Inc.Passive investorat least 5.3%−1.7 pts(filed with 1 related holder)Since 30 September 2026
- Armistice Capital, LLCPassive investorat least 5.0%−5.0 pts(filed with 1 related holder)Since 31 March 2025
- Ayrton Capital LLCPassive investorat least 4.1%−5.8 pts(filed with 2 related holders)Since 30 September 2025
| Holder | Stake | Since | |
|---|---|---|---|
Knight Therapeutics Inc. Passive investor | 19.9%+19.9 pts | 22 July 2026 | |
Mitchell P. Kopin Passive investor | at least 10.0%+0.9 pts (filed with 2 related holders) | 30 September 2026 | |
Orca Capital AG Passive investor | 5.6%+0.7 pts | 5 November 2026 | |
Lind Global Fund III LP Passive investor | at least 5.5% (filed with 2 related holders) | 31 July 2026 | |
CVI Investments, Inc. Passive investor | at least 5.3%−1.7 pts (filed with 1 related holder) | 30 September 2026 | |
Armistice Capital, LLC Passive investor | at least 5.0%−5.0 pts (filed with 1 related holder) | 31 March 2025 | |
Ayrton Capital LLC Passive investor | at least 4.1%−5.8 pts (filed with 2 related holders) | 30 September 2025 |
From Schedule 13D and 13G filings: anyone owning more than 5% must file one.
What insiders did
In the last 12 months, 1 insider bought $30,085 of shares on the open market.
- DOW GEOFFREY SPresident and CEO, DirectorBought
- Date
- 12 June 2026
- Shares
- 7,350
- Price
- $1.38
- Value
- $10,143
- DOW GEOFFREY SPresident and CEO, DirectorBought
- Date
- 15 December 2025
- Shares
- 9,670
- Price
- $0.80
- Value
- $7,736
- DOW GEOFFREY SPresident and CEO, DirectorBought
- Date
- 11 December 2025
- Shares
- 3,613
- Price
- $0.92
- Value
- $3,324
- DOW GEOFFREY SPresident and CEO, DirectorBought
- Date
- 10 December 2025
- Shares
- 9,350
- Price
- $0.95
- Value
- $8,883
| Date | Who | Did | Shares | Price | Value |
|---|---|---|---|---|---|
| 12 June 2026 | DOW GEOFFREY S President and CEO, Director | Bought | 7,350 | $1.38 | $10,143 |
| 15 December 2025 | DOW GEOFFREY S President and CEO, Director | Bought | 9,670 | $0.80 | $7,736 |
| 11 December 2025 | DOW GEOFFREY S President and CEO, Director | Bought | 3,613 | $0.92 | $3,324 |
| 10 December 2025 | DOW GEOFFREY S President and CEO, Director | Bought | 9,350 | $0.95 | $8,883 |
From Form 4 filings: insiders must report trades in their own company's shares within two days.
Warning signs in its filings
Problems the company itself reported to the SEC, in its own words.
2 serious warning signs in 60 Degrees Pharmaceuticals’ filings.
We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.
We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 30 Mar 2026, plus the 10-Q filed 16 Nov 2026 and 13 later 8-Ks.
Doubt it can keep going
SeriousThe company or its auditor warned it may not have enough money to last the next year.
“These conditions, among others, raise substantial doubt about the ability of the Company to continue as a going concern for one year from the date these consolidated condensed financial statements are issued.”
Show the full paragraph
Continuation as a going concern is dependent upon the Company’s ability to meet its financial requirements, raise additional capital, and achieve gross profitability from the Company’s single marketed product. To achieve profitability, the Company expects it will need to raise additional capital to fund its activities relating to commercial support for its existing product and any future clinical research trials and operating activities. However, there can be no assurance that it will ever achieve or maintain profitability. Accordingly, there is no assurance that the Company will be able to obtain the additional capital necessary to fund its operations during the look ‑ forward period. These conditions, among others, raise substantial doubt about the ability of the Company to continue as a going concern for one year from the date these consolidated condensed financial statements are issued.
From the 10-Q filed 16 November 2026, Part I, Item 1. Financial Statements. Read it in the filing
Weak checks on its own accounts
SeriousThe company said its checks on its own accounts did not work at the end of its latest quarter. Mistakes could slip into the numbers.
“Based on that evaluation, our Chief Executive Officer and the Company’s Chief Financial Officer have concluded that as of September 30, 2026 , due to the existence of the material weakness in our internal control over financial reporting described below, our disclosure controls and procedures were not effective.”
Show the full paragraph
Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, have evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of September 30, 2026 . Based on that evaluation, our Chief Executive Officer and the Company’s Chief Financial Officer have concluded that as of September 30, 2026 , due to the existence of the material weakness in our internal control over financial reporting described below, our disclosure controls and procedures were not effective.
From the 10-Q filed 16 November 2026, Part I, Item 4. Controls and Procedures. Read it in the filing
One big customer
Worth knowingOne customer brings in a big share of sales: 92% last year. Losing that customer would hurt.
“For the year ended December 31, 2025, our U.S. pharmaceutical distributor accounted for 92% of our total net product sales and Kodatef sales to our Australian distributor accounted for 6% of total net product sales (95% and 5% for the year ended December 31, 2024, respectively).”
From the 10-K filed 30 March 2026, Item 7. Management's Discussion and Analysis. Read it in the filing
A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.
The deep dive
Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.
- What the business is worth, as a range, and the margin of safety at today’s price
- Prices to start buying, buy, and buy hard
- The three things that would make this a mistake
- Every number footnoted to the filing it came from
Your first deep dive is free.
Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.